CNTB — Connect Biopharma Holdings Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1835268 ·
Last close
$2.02
Market Cap
$127.19M
52W High
$2.83
52W Low
$1.92
ADV30
546,263
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 169,000 | — | -19,607,000 | -19,398,000 | 60,066,000 | 46,034,000 | 17,443,000 |
| Dec 2025 | 0 | — | -15,526,000 | -15,109,000 | 56,075,000 | 38,345,000 | 14,095,000 |
| Sep 2025 | 16,000 | — | -17,677,000 | -17,200,000 | 67,361,000 | 37,845,000 | 11,990,000 |
| Jun 2025 | 48,000 | — | -13,424,000 | -12,899,000 | 82,725,000 | 40,632,000 | 11,383,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-57,252,000
Investing CF
$36,459,000
Financing CF
$18,713,000
CapEx
$-434,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.15
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-420,233,000
Inventory
—
Receivables
$2,701,000
ST Investments
$0
EBIT TTM
$-66,234,000
Pretax Income TTM
$-64,415,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$233,000
EBITDA
$-65,539,000
Free Cash Flow
$-33,877,248
Enterprise Value
$81,845,984
Total Cash
$46,034,000
Total Debt
$693,000
Shares Out
62,963,853
Trailing EPS
$-1.15
Book Value
$0.68
ROE
-102.9%
ROA
-54.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 64,000 | -58,074,000 | -55,480,000 | 56,075,000 | 14,095,000 | — | -51,206,000 |
| Dec 2024 | 26,033,000 | -22,452,000 | -15,628,000 | 101,284,000 | 9,118,000 | — | -23,612,000 |
| Dec 2023 | 0 | -69,056,000 | -62,106,000 | 127,375,000 | 25,878,000 | — | -47,741,000 |
| Dec 2022 | 0 | -116,507,000 | -118,091,000 | 174,013,000 | 16,521,000 | — | -101,520,000 |
TTM Snapshot
Revenues TTM
$1,219,000
NetIncome TTM
$-12,876,000
OpCashFlow TTM
$0
Assets (Latest)
$101,284,000
Forward EPS
$-0.78
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VTVT | vTv Therapeutics Inc. | $127.42M | $32.35 | — |
| TLSA | Tiziana Life Sciences Ltd | $131.08M | $1.03 | — |
| PMN | ProMIS Neurosciences Inc. | $123.04M | $13.72 | — |
| GNLX | GENELUX Corp | $131.83M | $2.94 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $132.19M | $0.94 | — |
News headlines (Yahoo Finance, 1h cache)
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
2026-06-17 13:00 · Yahoo
Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026
2026-05-22 04:05 · Yahoo
Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite Risky
2026-05-15 13:40 · Yahoo
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
2026-05-12 20:05 · Yahoo
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 13:00 · Yahoo
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
2026-04-23 13:00 · Yahoo
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
2026-04-07 15:00 · Yahoo
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
2026-03-31 20:05 · Yahoo
Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impresses
2026-03-30 14:11 · Yahoo
Connect Biopharma Announces $20.2 Million Private Placement Financing
2026-03-30 11:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.